Mark Stevens, PhD

Pharmacology and Toxicology
Pharmacology and Toxicology
Dissertation Title: 
“Distinct Functions of MEKK3 and MEKK4 during Heart Valve Morphogenesis”

Year Graduated: 2008
Career Type: Government
Post Doctoral Fellow, National Institutes of Health NHLBI/TMB

Academic & Professional Updates
I am currently doing my post-doctoral training in the laboratory of Dr. Michael Sack, MD, PhD at the National Institutes of Health. My project is to decipher mitochondrial mechanisms of cardioprotection. Mitochondria are not only involved in energy production, but also in reactive oxygen species regulation and apoptosis. This makes them an excellent target for cytoprotective strategies. Findings from this project will be advanced to the clinic, which we are closely involved.

1. Meadows KN, Iyer S, Stevens MV, Wang D, Shechter S, Perruzzi CA, Camenisch TD and Benjamin LE. Akt promotes Endocardial-Mesenchyme Transition. Accepted to Journal of Angiogenesis Research on July, 2009.
2. Stevens MV, Broka D, Parker P, Rogowitz E, Vaillancourt RR, Camenisch TD. MEKK3 initiates TGFβ2-dependent EMT during endocardial cushion morphogenesis. December 2008 Circ. Res. 103:pp 1430-40.
3. Craig EA, Stevens MV, Vaillancourt RR, Camenisch TD. MAP3Ks regulate cell fate during development. November 2008 Dev Dyn. 237:pp 3102-14.
4. Stevens MV, Parker P, Vaillancourt RR, Camenisch TD. MEKK4 regulates developmental EMT in the embryonic heart. October 2006 Dev Dyn. 235:pp 2761-70.
5. Klewer SE, Yatskievych T, Pogreba K, Stevens MV, Antin PB, Camenisch TD. Has2 expression in heart forming regions is independent of BMP signaling. June 2006 Gene Expr Patterns 6:pp 462-70.
6. Camenisch TD, Lopez JI, Stevens MV, Sands BJ, McDonald JA, and Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. August 2005 Cancer Research 65:pp 6755-63.
Originally posted: August 21, 2014
Last updated: October 8, 2015
Want to update? Contact Webmaster
Share This